HC Wainwright Increases KalVista Pharmaceuticals (NASDAQ:KALV) Price Target to $37.00

KalVista Pharmaceuticals (NASDAQ:KALV) had its target price increased by investment analysts at HC Wainwright from $27.00 to $37.00 in a report issued on Friday,Benzinga reports. The firm presently has a “buy” rating on the specialty pharmaceutical company’s stock. HC Wainwright’s price objective indicates a potential upside of 133.88% from the stock’s previous close.

Other equities research analysts also recently issued reports about the company. Citizens Jmp dropped their price objective on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a report on Tuesday, November 11th. Weiss Ratings restated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research note on Wednesday, October 8th. Cowen reaffirmed a “buy” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, December 3rd. Wall Street Zen upgraded shares of KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. Finally, Citigroup reissued a “market outperform” rating on shares of KalVista Pharmaceuticals in a research report on Tuesday, November 11th. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $29.17.

KalVista Pharmaceuticals Stock Performance

Shares of KALV stock opened at $15.82 on Friday. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21. The company’s fifty day moving average price is $14.45 and its two-hundred day moving average price is $13.55. The firm has a market capitalization of $799.64 million, a P/E ratio of -4.01 and a beta of -0.14. KalVista Pharmaceuticals has a 12 month low of $7.30 and a 12 month high of $17.30.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its earnings results on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.96) by $0.04. The business had revenue of $13.69 million for the quarter, compared to analysts’ expectations of $6.03 million. On average, research analysts anticipate that KalVista Pharmaceuticals will post -3.56 earnings per share for the current fiscal year.

Insider Buying and Selling at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 5,296 shares of the stock in a transaction on Monday, November 24th. The shares were sold at an average price of $13.45, for a total transaction of $71,231.20. Following the sale, the insider directly owned 131,831 shares of the company’s stock, valued at approximately $1,773,126.95. This represents a 3.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Benjamin L. Palleiko sold 7,294 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $16.51, for a total transaction of $120,423.94. Following the completion of the transaction, the chief executive officer directly owned 424,520 shares of the company’s stock, valued at $7,008,825.20. This trade represents a 1.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 31,329 shares of company stock worth $437,371 over the last 90 days. Insiders own 4.30% of the company’s stock.

Institutional Trading of KalVista Pharmaceuticals

Several hedge funds have recently made changes to their positions in the stock. BNP Paribas Financial Markets boosted its position in KalVista Pharmaceuticals by 47.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after purchasing an additional 1,292 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in KalVista Pharmaceuticals in the third quarter valued at $55,000. Wolverine Asset Management LLC acquired a new position in shares of KalVista Pharmaceuticals during the third quarter valued at $57,000. KLP Kapitalforvaltning AS acquired a new position in shares of KalVista Pharmaceuticals during the third quarter valued at $63,000. Finally, Virtus Investment Advisers LLC bought a new position in shares of KalVista Pharmaceuticals during the second quarter worth about $81,000.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.